The global Automated Cell Biology Systems market is poised for significant growth, transitioning from a niche to a core productivity tool for the life sciences sector by 2035. This evolution is driven by the need to expedite drug development and the industrial scaling of advanced therapies, such as cell and gene treatments. The market is bifurcating into high-value integrated platforms for complex applications and volume-driven standardized workflows, leading to varied strategies among manufacturers. Demand is particularly strong in drug discovery, biopharmaceutical production, and regenerative medicine, with investments supporting sustained growth. Key players include Thermo Fisher Scientific, Danaher, and Sartorius, while North America leads market share due to its advanced R&D ecosystem. The Asia-Pacific region is expected to emerge as the fastest-growing market, fueled by substantial investments and government initiatives. Overall, the market is projected to grow at a compound annual growth rate of 8.7% from 2026 to 2035.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/automated-cell-biology-systems-market-to-2035-driven-by-industrial-scaling-of-cell-and-gene-therapies/
